Maryann Cimino - Pharvaris Director Relations
| PHVS Stock | USD 21.90 0.46 2.06% |
Insider
Maryann Cimino is Director Relations of Pharvaris BV
| Address | Emmy Noetherweg 2, Leiden, Netherlands, 2333 BK |
| Phone | 31 71 203 6410 |
| Web | https://pharvaris.com |
Pharvaris Management Efficiency
The company has return on total asset (ROA) of (0.2679) % which means that it has lost $0.2679 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4505) %, meaning that it created substantial loss on money invested by shareholders. Pharvaris' management efficiency ratios could be used to measure how well Pharvaris manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.27 in 2024. Return On Capital Employed is likely to drop to -0.26 in 2024. At this time, Pharvaris' Total Assets are comparatively stable compared to the past year. Non Current Assets Total is likely to gain to about 885.3 K in 2024, whereas Return On Tangible Assets are likely to drop (0.27) in 2024.Similar Executives
| Showing other executives | INSIDER Age | ||
| FACC MD | Stoke Therapeutics | 61 | |
| MBA MD | Ikena Oncology | 59 | |
| Paul MD | AN2 Therapeutics | 54 | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| CPA CPA | Stoke Therapeutics | 63 | |
| Josh Eizen | AN2 Therapeutics | N/A | |
| Sharon Townson | Monte Rosa Therapeutics | 49 | |
| Rex CFA | Anebulo Pharmaceuticals | 64 | |
| Arnold Levine | Pmv Pharmaceuticals | 84 | |
| , MBA | Molecular Partners AG | 51 | |
| Scott Anderson | Anebulo Pharmaceuticals | N/A | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Daniel Hicklin | Werewolf Therapeutics | 60 | |
| MBA MD | Eliem Therapeutics | 63 | |
| Michelle Zhang | Ikena Oncology | N/A | |
| Joan Wood | Stoke Therapeutics | N/A | |
| Thomas Shenk | Pmv Pharmaceuticals | 77 | |
| Amy Conrad | Tyra Biosciences | N/A | |
| Ellen MBA | Werewolf Therapeutics | 48 | |
Management Performance
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 |
Pharvaris BV Leadership Team
Elected by the shareholders, the Pharvaris' board of directors comprises two types of representatives: Pharvaris inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pharvaris. The board's role is to monitor Pharvaris' management team and ensure that shareholders' interests are well served. Pharvaris' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pharvaris' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Peng MD, Chief Officer | ||
| Morgan Conn, Chief Officer | ||
| Jochen Knolle, Chief COO | ||
| CPA MBA, CEO CoFounder | ||
| Joan JD, Chief Officer | ||
| Stefan Abele, Chief Officer | ||
| Wim Souverijns, Chief Officer | ||
| Anne Lesage, Chief Officer | ||
| David JD, CFO Secretary | ||
| RA MSc, Head Officer | ||
| Maryann Cimino, Director Relations | ||
| Annick Deschoolmeester, Chief Officer |
Pharvaris Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pharvaris a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.45 | ||||
| Return On Asset | -0.27 | ||||
| Current Valuation | 892.61 M | ||||
| Shares Outstanding | 54.23 M | ||||
| Shares Owned By Insiders | 9.49 % | ||||
| Shares Owned By Institutions | 87.50 % | ||||
| Number Of Shares Shorted | 183.25 K | ||||
| Price To Book | 3.89 X | ||||
| EBITDA | (96.85 M) | ||||
| Net Income | (99.83 M) |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Pharvaris Stock Analysis
When running Pharvaris' price analysis, check to measure Pharvaris' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pharvaris is operating at the current time. Most of Pharvaris' value examination focuses on studying past and present price action to predict the probability of Pharvaris' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pharvaris' price. Additionally, you may evaluate how the addition of Pharvaris to your portfolios can decrease your overall portfolio volatility.